EDGAR·FLOW

Annovis Bio, Inc. — Form 8-K

Filed November 13, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 78/100
What the filing says
Annovis closed an underwritten public offering on November 6, 2026, raising $21.0 million gross proceeds (with the Board Chairman contributing $5.0 million). The company's pivotal Phase 3 DUET-AD trial in Alzheimer's disease is fully enrolled with 862 patients; last patient/last visit scheduled December 31, 2026, database lock February 8, 2027, and topline 6-month results in March 2027. Cash and equivalents fell from $19.5M (Dec 2025) to $2.8M (Sept 2026); the $21M offering is intended to fund operations through the 6-month data readout.
Why this rating

Financing is material (58% of current market cap) and critical to reaching pivotal Phase 3 readout. Data readout in March 2027 is transformational inflection point for ~$36M company, but outcome is uncertain. Raises runway risk post-readout.

Price action (we called it neutral)
before filing · preread
$0.95 ▲ 2.42%
at our read · unknown
$0.93
+10 min · unknown
$0.89 ▼ 4.01%
+30 min · unknown
$0.90 ▼ 2.56%
+1 hr · unknown
$0.80 ▼ 13.41%
+4 hrs · unknown
$0.78 ▼ 15.68%

The stock had already moved -2.36% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ANVS · stock on Yahoo Finance ↗

See more from November 13, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.